共 50 条
Management of Upper Tract Urothelial Carcinoma
被引:21
|作者:
Shvero, Asaf
[1
,2
,3
]
Hubosky, Scott G.
[1
]
机构:
[1] Thomas Jefferson Univ, Thomas Jefferson Univ Hosp, Sidney Kimmel Med Coll, Dept Urol, 1025 Walnut St,Suite 1100, Philadelphia, PA 19107 USA
[2] Sheba Med Ctr, Dept Urol, Ramat Gan, Israel
[3] Tel Aviv Univ, Tel Aviv, Israel
关键词:
Upper tract urothelial carcinoma;
Ureteroscopy;
Nephron-sparing surgery;
Laser ablation;
Nephroureterectomy;
Topical chemotherapy;
Systemic chemotherapy;
UPPER URINARY-TRACT;
CISPLATIN-INELIGIBLE PATIENTS;
BLADDER-CANCER;
RADICAL NEPHROURETERECTOMY;
ONCOLOGIC OUTCOMES;
LYNCH SYNDROME;
NEOADJUVANT CHEMOTHERAPY;
DIAGNOSTIC URETEROSCOPY;
SINGLE-ARM;
MULTICENTER;
D O I:
10.1007/s11912-021-01179-8
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Purpose of Review We review the epidemiology, risk factors, diagnosis, and treatment of upper tract urothelial carcinoma (UTUC), with a distinction between the different risk groups. Recent Findings Endoscopic treatment with laser ablation of tumors has an evolving role in treating low-grade UTUC including select large and multifocal tumors, along with complementary topical chemotherapeutic treatment that can reach difficult intrarenal locations. Template lymphadenectomy is recommended in patients undergoing nephroureterectomy. A recent randomized control trial showed benefit of adjuvant chemotherapy after radical nephroureterectomy for locally advanced disease. Advances in immunologic therapy have shown promise in treating metastatic UTUC, and immunologic-based therapies have been incorporated into treatment regimens. Notable progress has been made in both the surgical and medical treatment arms for UTUC, thus extending the reach of nephron-sparing therapy for those with localized disease and increasing overall survival for those with locally advanced disease.
引用
收藏
页码:611 / 619
页数:9
相关论文